title: Health economics of insomnia therapy: implications for policy.
abstract: Chronic primary insomnia is a major public health problem causing significant burden for those affected. Rising health care costs may cause increased financial pressures on governments and private payers, forcing stricter cost-control measures and, as a result, insomnia, often considered a lifestyle condition, may not receive the proper attention it deserves. In order to highlight the benefits that can be achieved through successful treatment of insomnia, there is a need for further comparative studies of existing and emerging treatments, cost burden of illness and cost-effectiveness analyses. Health economic assessment of insomnia and its treatments is an emerging area. The development of comprehensive assessment of insomnia treatments, however, has been hindered by complexities and gaps in the available data. Health economic models of insomnia, such as the one detailed here, should enable researchers to better address the effects of different treatments on clinical and economic measures for insomnia and related comorbidities. It is apparent that research into the cost-effectiveness of therapies for insomnia is in its infancy and further work is needed.
authors: Pharmerit North America LLC, 7272 Wisconsin Ave, Suite 300, Bethesda, MD 20814, USA. mbotteman@pharmerit.com
authors: Marc
authors: M
authors: Botteman
mesh_terms: D002908:Chronic Disease; D015928:Cognitive Behavioral Therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000191:economics / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology; D019057:Quality-Adjusted Life Years; D007319:Sleep Initiation and Maintenance Disorders / Q000191:economics* / Q000523:psychology / Q000628:therapy
chemical_list: D006993:Hypnotics and Sedatives